NewAmsterdam Pharma (NASDAQ:NAMS) Issues Earnings Results

NewAmsterdam Pharma (NASDAQ:NAMS) released its quarterly earnings data on Wednesday. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04), FiscalAI reports. NewAmsterdam Pharma had a negative net margin of 3,644.21% and a negative return on equity of 34.05%. The company had revenue of $3.70 million for the quarter, compared to analyst estimates of $2.83 million.

Here are the key takeaways from NewAmsterdam Pharma’s conference call:

• European regulatory progress: Obicetrapib received a positive CHMP recommendation, with EMA approval and Menarini-led launches in the U.K. and Germany anticipated by late Q4 2026.
• PREVAIL remains the central catalyst. Management said blinded event rates are tracking favorably against BROADWAY and that an interim analysis could occur in Q1 2027, while retaining the option to continue the trial through the end of 2027 to maximize statistical power.
• The company highlighted broad lipid effects beyond LDL reduction, including more than 40% LDL lowering with obicetrapib monotherapy, roughly 60% with the ezetimibe fixed-dose combination, substantial HDL increases, and reductions in Lp(a) and small LDL particles. These claims remain dependent on ongoing outcomes validation.
• Commercial preparations are accelerating amid a growing lipid-treatment market, expanded treatment guidelines, and a large undertreated patient population. NewAmsterdam said it has more than $678 million in cash and has expanded its commercial and medical-affairs leadership ahead of potential launches.
• The company is advancing additional programs, including RUBENS in patients with diabetes and metabolic syndrome, REMBRANDT for plaque imaging with the fixed-dose combination, and SPINOZA to evaluate Alzheimer’s-related biomarkers in APOE4 carriers. These programs could broaden differentiation but remain investigational and are not yet established clinical benefits.

NewAmsterdam Pharma Stock Up 1.0%

NASDAQ:NAMS traded up $0.29 during mid-day trading on Friday, reaching $27.96. 572,003 shares of the company were exchanged, compared to its average volume of 1,031,324. NewAmsterdam Pharma has a 12 month low of $23.05 and a 12 month high of $42.21. The company has a fifty day moving average of $31.49 and a 200 day moving average of $32.53. The stock has a market cap of $3.27 billion, a PE ratio of -12.94 and a beta of 0.10.

Insider Buying and Selling at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 105,000 shares of the business’s stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $30.34, for a total value of $3,185,700.00. Following the completion of the transaction, the chief accounting officer directly owned 24,353 shares of the company’s stock, valued at approximately $738,870.02. The trade was a 81.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders have sold 210,000 shares of company stock valued at $6,713,550 over the last ninety days. Insiders own 12.74% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of NAMS. Wells Fargo & Company MN raised its position in shares of NewAmsterdam Pharma by 50.0% during the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock worth $32,000 after acquiring an additional 300 shares during the last quarter. Empowered Funds LLC bought a new position in NewAmsterdam Pharma in the fourth quarter valued at about $85,000. Persistent Asset Partners Ltd acquired a new stake in NewAmsterdam Pharma in the fourth quarter worth about $138,000. The Manufacturers Life Insurance Company increased its position in NewAmsterdam Pharma by 5.3% in the second quarter. The Manufacturers Life Insurance Company now owns 10,868 shares of the company’s stock worth $197,000 after purchasing an additional 544 shares during the period. Finally, Guggenheim Capital LLC bought a new stake in NewAmsterdam Pharma during the 4th quarter worth about $224,000. Institutional investors and hedge funds own 89.89% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently commented on NAMS. Royal Bank Of Canada decreased their price target on NewAmsterdam Pharma from $51.00 to $50.00 and set an “outperform” rating on the stock in a research note on Thursday. Wall Street Zen upgraded NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Jefferies Financial Group reissued a “buy” rating and set a $45.00 price objective on shares of NewAmsterdam Pharma in a report on Monday, July 20th. BMO Capital Markets assumed coverage on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. They issued an “outperform” rating and a $58.00 target price on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Friday, July 17th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $49.33.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical?stage biopharmaceutical company focused on discovering and developing novel small?molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small?molecule candidates at various stages of preclinical and clinical evaluation.